| Literature DB >> 23324440 |
Domenico Otranto1, Filipe Dantas-Torres, Emanuele Brianti, Donato Traversa, Dusan Petrić, Claudio Genchi, Gioia Capelli.
Abstract
Presently, 45% of the total human population of Europe, as well as their domestic and companion animals, are exposed to the risk of vector-borne helminths (VBH) causing diseases. A plethora of intrinsic biological and extrinsic factors affect the relationship among helminths, vectors and animal hosts, in a constantly changing environment. Although canine dirofilarioses by Dirofilaria immitis and Dirofilaria repens are key examples of the success of VBH spreading into non-endemic areas, another example is represented by Thelazia callipaeda eyeworm, an emergent pathogen of dogs, cats and humans in several regions of Europe. The recent finding of Onchocerca lupi causing canine and human infestation in Europe and overseas renders the picture of VBH even more complicated. Similarly, tick-transmitted filarioids of the genus Cercopithifilaria infesting the skin of dogs were recently shown to be widespread in Europe. Although for most of the VBH above there is an increasing accumulation of research data on their distribution at national level, the overall impact of the diseases they cause in dogs and humans is not fully recognised in many aspects. This review investigates the reasons underlying the increasing trend in distribution of VBH in Europe and discusses the diagnostic and control strategies currently available. In addition, this article provides the authors' opinion on some topics related to VBH that would deserve further scientific investigation.Entities:
Mesh:
Year: 2013 PMID: 23324440 PMCID: PMC3564894 DOI: 10.1186/1756-3305-6-16
Source DB: PubMed Journal: Parasit Vectors ISSN: 1756-3305 Impact factor: 3.876
Figure 1Culex pipiens pipiens feeding on a human host (Courtesy of Fabrizio Montarsi).
Figure 2Stegomyia albopicta feeding on a human host (Courtesy of Nediljko Landeka).
Figure 3Distribution of spp., and in Europe. Map of Europe showing the distribution of Acanthocheilonema reconditum, Cercopithifilaria sp.1, Onchocerca lupi and Thelazia callipaeda.
Figure 4Distribution of , and . in Italy. Map of Italy showing the spread of the distribution of the mosquito Stegomyia albopicta [Ae. albopictus] (left), of Dirofilaria immitis in dogs (centre) and Dirofilaria repens (right). For D. immitis and D. repens the classes after 1997 correspond to the first report in the region [47,53] and/or an upsurge of the prevalence in dogs compared to the past.
Figure 5in Europe. Distribution of Dirofilaria immitis in dogs up to 2001 and later on. Modified from [3].
Figure 6in Europe. Distribution of Dirofilaria repens in dogs up to 2001 and later on. Modified from [3].
Macrocyclic lactones and dosages licensed in different formulations for the prevention of infestations caused by (Di) or (Dr) in dogs
| Ivermectin | Tablets/Chewables | 6 mcg/kg | Di, Dr |
| Ivermectin/Praziquantel | Chewables | 6 mcg/kg / 5 mg/kg | Di, Dr |
| Milbemycin oxime* | Tablets | 0.5 mg/kg | Di |
| Moxidectin | Tablets | 3 mcg/kg | Di |
| | Injectable | 0.17 mcg/kg | Di, Dr |
| Moxidectin/Imidacloprid | Spot on | 2.5 mg/Kg / 10 mg/kg | Di |
| Selamectin | Spot on | 6 mg/kg | Di |
*Tablets containing either praziquantel or lufenuron are also available for chemoprevention at the same dosage (modified from [66]).